## Abstract High levels of HIV‐1 replication occur following perinatal infection and antiretroviral drugs may not fully suppress viral load during the early years of childhood. Adherence to treatment may also be difficult among children. These two factors will contribute to development of drug resi
Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children
✍ Scribed by Constance Delaugerre; Josiane Warszawski; Marie-Laure Chaix; Florence Veber; Eugenia Macassa; Florence Buseyne; Christine Rouzioux; Stéphane Blanche
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 157 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
In the USA and West Europe, nearly 80% of HIV‐1‐infected adults, experiencing virologic failure, harbored virus strain resistant to at least one antiretroviral drug. Limited data are available on antiretroviral drug resistance in pediatric HIV infection. The aims of this study were to analyze prevalence of HIV‐1 drug resistance and to identify risk factors associated with resistance in this population. Prevalence of genotypic resistance was estimated retrospectively in treated children who experienced virologic failure (with HIV‐1‐RNA > 500 copies/ml) followed in Necker hospital between 2001 and 2003. Among 119 children with resistance testing, prevalence of resistance to any drug was 82.4%. Resistance ranged from 76.5% to nucleoside reverse transcriptase inhibitor (NRTI), to 48.7% to non‐nucleoside reverse transcriptase inhibitor (NNRTI) and 42.9% to protease inhibitor (PI). Resistance to at least one drug of two classes and three classes (triple resistance) was 31.9 and 26.9%, respectively. Resistance was not associated with geographic origin, HIV‐1 subtype, and CDC status. In multivariate analysis, resistance to any drug remained associated independently with current low viral load and high lifetime number of past PI. Triple resistance was independently associated with the high lifetime number of past PI and with gender, particularly among children aged 11 years old or more with a prevalence seven times higher in boys than in girls. In conclusion, antiretroviral resistance is common among treated HIV‐1‐infected children and prevalence was similar with those observed in adult population in the same year period. However, adolescent boys seem to be at greater risk. J. Med. Virol. 79:1261–1269, 2007. © Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract The extent to which HIV‐1 proviral DNA mutations cause clinically relevant antiretroviral resistance is still controversial. Paired plasma HIV‐1 RNA and whole blood DNA were compared in patients failing HAART to investigate if the additional knowledge of archived mutations could improve
## Abstract Recently increased availability of anti‐retroviral therapy (ART) has mitigated HIV‐1/AIDS prognoses especially in resource poor settings. The emergence of ART resistance‐associated mutations from non‐suppressive ART has been implicated as a major cause of ART failure. Reverse transcript
## Abstract The HIV‐1 protease L76V mutation has been described recently as conferring high‐level resistance to lopinavir/ritonavir (LPV/r). The aim was to identify the factors and particularly protease mutations associated with the presence of L76V in treatment‐experienced patients infected with H
## Abstract This was an exploratory study to investigate lamivudine‐resistant hepatitis B virus (HBV) strains in selected lamivudine‐naïve HBV carriers with and without human immunodeficiency virus (HIV) co‐infection in South African patients. Thirty‐five lamivudine‐naïve HBV infected patients with
## Abstract The objective of the study was to estimate the prevalence of HIV‐1 resistance to all drugs belonging to two or more antiretroviral drug (ARV) classes in treated patients in France. All genotyping assays performed in June 2001 and in November 2002 by the ANRS resistance laboratory networ